BMY vs. BIIB
Compare and contrast key facts about Bristol-Myers Squibb Company (BMY) and Biogen Inc. (BIIB).
Performance
BMY vs. BIIB - Performance Comparison
Loading graphics...
BMY vs. BIIB - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
BMY Bristol-Myers Squibb Company | 13.77% | 0.11% | 15.81% | -26.14% | 18.98% | 2.88% | 0.41% | 27.74% | -12.90% | 7.71% |
BIIB Biogen Inc. | 4.17% | 15.09% | -40.91% | -6.55% | 15.42% | -2.02% | -17.48% | -1.39% | -5.54% | 12.34% |
Fundamentals
BMY:
$123.79B
BIIB:
$26.89B
BMY:
$3.46
BIIB:
$8.82
BMY:
17.53
BIIB:
20.77
BMY:
1.00
BIIB:
1.44
BMY:
2.57
BIIB:
2.74
BMY:
2.22
BIIB:
1.47
BMY:
$48.19B
BIIB:
$9.81B
BMY:
$30.43B
BIIB:
$6.91B
BMY:
$13.82B
BIIB:
$3.10B
Returns By Period
In the year-to-date period, BMY achieves a 13.77% return, which is significantly higher than BIIB's 4.17% return. Over the past 10 years, BMY has outperformed BIIB with an annualized return of 2.72%, while BIIB has yielded a comparatively lower -3.45% annualized return.
BMY
- 1D
- 1.54%
- 1M
- -2.76%
- YTD
- 13.77%
- 6M
- 37.94%
- 1Y
- 4.47%
- 3Y*
- 0.11%
- 5Y*
- 3.12%
- 10Y*
- 2.72%
BIIB
- 1D
- -2.26%
- 1M
- -4.43%
- YTD
- 4.17%
- 6M
- 30.88%
- 1Y
- 33.97%
- 3Y*
- -12.96%
- 5Y*
- -8.04%
- 10Y*
- -3.45%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BMY vs. BIIB — Risk / Return Rank
BMY
BIIB
BMY vs. BIIB - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Bristol-Myers Squibb Company (BMY) and Biogen Inc. (BIIB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| BMY | BIIB | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.16 | 0.99 | -0.83 |
Sortino ratioReturn per unit of downside risk | 0.43 | 1.63 | -1.21 |
Omega ratioGain probability vs. loss probability | 1.05 | 1.19 | -0.14 |
Calmar ratioReturn relative to maximum drawdown | 0.22 | 1.90 | -1.67 |
Martin ratioReturn relative to average drawdown | 0.35 | 4.80 | -4.45 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| BMY | BIIB | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.16 | 0.99 | -0.83 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.13 | -0.21 | +0.34 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.11 | -0.08 | +0.19 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.35 | 0.22 | +0.13 |
Correlation
The correlation between BMY and BIIB is 0.29, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
BMY vs. BIIB - Dividend Comparison
BMY's dividend yield for the trailing twelve months is around 4.11%, while BIIB has not paid dividends to shareholders.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BMY Bristol-Myers Squibb Company | 4.11% | 4.60% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% |
BIIB Biogen Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Drawdowns
BMY vs. BIIB - Drawdown Comparison
The maximum BMY drawdown since its inception was -72.03%, smaller than the maximum BIIB drawdown of -89.98%. Use the drawdown chart below to compare losses from any high point for BMY and BIIB.
Loading graphics...
Drawdown Indicators
| BMY | BIIB | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -72.03% | -89.98% | +17.95% |
Max Drawdown (1Y)Largest decline over 1 year | -25.79% | -14.13% | -11.66% |
Max Drawdown (5Y)Largest decline over 5 years | -47.67% | -72.66% | +24.99% |
Max Drawdown (10Y)Largest decline over 10 years | -47.67% | -72.66% | +24.99% |
Current DrawdownCurrent decline from peak | -13.61% | -61.48% | +47.87% |
Average DrawdownAverage peak-to-trough decline | -22.40% | -36.48% | +14.08% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 17.63% | 6.78% | +10.85% |
Volatility
BMY vs. BIIB - Volatility Comparison
The current volatility for Bristol-Myers Squibb Company (BMY) is 6.67%, while Biogen Inc. (BIIB) has a volatility of 8.91%. This indicates that BMY experiences smaller price fluctuations and is considered to be less risky than BIIB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| BMY | BIIB | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.67% | 8.91% | -2.24% |
Volatility (6M)Calculated over the trailing 6-month period | 19.42% | 24.16% | -4.74% |
Volatility (1Y)Calculated over the trailing 1-year period | 28.60% | 34.48% | -5.88% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 23.66% | 38.11% | -14.45% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 25.08% | 41.40% | -16.32% |
Financials
BMY vs. BIIB - Financials Comparison
This section allows you to compare key financial metrics between Bristol-Myers Squibb Company and Biogen Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
BMY vs. BIIB - Profitability Comparison
BMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Bristol-Myers Squibb Company reported a gross profit of 6.24B and revenue of 12.50B. Therefore, the gross margin over that period was 49.9%.
BIIB - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Biogen Inc. reported a gross profit of 1.78B and revenue of 2.28B. Therefore, the gross margin over that period was 78.2%.
BMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Bristol-Myers Squibb Company reported an operating income of 1.47B and revenue of 12.50B, resulting in an operating margin of 11.8%.
BIIB - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Biogen Inc. reported an operating income of -57.00M and revenue of 2.28B, resulting in an operating margin of -2.5%.
BMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Bristol-Myers Squibb Company reported a net income of 1.09B and revenue of 12.50B, resulting in a net margin of 8.7%.
BIIB - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Biogen Inc. reported a net income of -48.41M and revenue of 2.28B, resulting in a net margin of -2.1%.